JP2017501728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501728A5 JP2017501728A5 JP2016543004A JP2016543004A JP2017501728A5 JP 2017501728 A5 JP2017501728 A5 JP 2017501728A5 JP 2016543004 A JP2016543004 A JP 2016543004A JP 2016543004 A JP2016543004 A JP 2016543004A JP 2017501728 A5 JP2017501728 A5 JP 2017501728A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- amino acid
- binding fragment
- terminal amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920425P | 2013-12-23 | 2013-12-23 | |
| US61/920,425 | 2013-12-23 | ||
| PCT/CA2014/051263 WO2015095972A1 (en) | 2013-12-23 | 2014-12-23 | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501728A JP2017501728A (ja) | 2017-01-19 |
| JP2017501728A5 true JP2017501728A5 (cg-RX-API-DMAC7.html) | 2018-02-01 |
| JP6585600B2 JP6585600B2 (ja) | 2019-10-02 |
Family
ID=53477259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543004A Active JP6585600B2 (ja) | 2013-12-23 | 2014-12-23 | Ｃ末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11208497B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3087185A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6585600B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160122127A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106459981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014373593B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016014913A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2934818C (cg-RX-API-DMAC7.html) |
| IL (1) | IL246371A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016008355A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016129724A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201605093VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015095972A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164723A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| WO2018071913A2 (en) * | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| US11541121B2 (en) | 2017-07-13 | 2023-01-03 | City Of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
| US11607457B2 (en) | 2017-07-13 | 2023-03-21 | City Of Hope | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same |
| US20200277383A1 (en) * | 2017-09-07 | 2020-09-03 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CN119410678A (zh) * | 2018-05-01 | 2025-02-11 | Ambrx公司 | 一种用于优化抗体表达的方法 |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| FI3886914T3 (fi) | 2018-11-30 | 2023-05-26 | Bristol Myers Squibb Co | Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| CN117164701A (zh) * | 2022-12-27 | 2023-12-05 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
| EP4548936A1 (en) * | 2023-10-30 | 2025-05-07 | BioNTech SE | Antibody-drug conjugates having a tailor-made drug-to-antibody ratio |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2170589C2 (ru) | 1992-10-28 | 2001-07-20 | Генентек Инк. | Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты) |
| WO1994011028A1 (en) * | 1992-11-16 | 1994-05-26 | Centocor, Inc. | Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US20050159343A1 (en) | 1999-03-26 | 2005-07-21 | Board Of Regents, University Of Texas System | Inhibitors of glycosaminoglycans |
| AU2001296494A1 (en) | 2000-10-02 | 2002-04-15 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for the transport of biologically active agents across cellular barriers |
| US7834258B2 (en) * | 2003-06-30 | 2010-11-16 | Mu-Hyeon Choe | Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
| WO2007103288A2 (en) * | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| SG183044A1 (en) * | 2007-07-16 | 2012-08-30 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugatesand methods of use |
| CA2694488A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8865875B2 (en) * | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| EA023031B1 (ru) * | 2007-11-30 | 2016-04-29 | Глаксо Груп Лимитед | Антиген-связывающая конструкция и ее применение |
| US20110189206A1 (en) | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
| US8454960B2 (en) * | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| CA3018235C (en) * | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| EP2635310A2 (en) | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| MX364707B (es) * | 2011-05-08 | 2019-05-06 | Legochem Biosciences Inc | Conjugados de proteina-agente activo y método para su preparación. |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| MX354663B (es) * | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i. |
| CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| SG11201404532XA (en) * | 2012-03-02 | 2014-08-28 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
| MX2015007931A (es) | 2012-12-18 | 2015-10-05 | Novartis Ag | Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano. |
-
2014
- 2014-12-23 CN CN201480075958.5A patent/CN106459981A/zh active Pending
- 2014-12-23 EP EP14874786.8A patent/EP3087185A4/en not_active Withdrawn
- 2014-12-23 BR BR112016014913A patent/BR112016014913A8/pt not_active Application Discontinuation
- 2014-12-23 CA CA2934818A patent/CA2934818C/en active Active
- 2014-12-23 JP JP2016543004A patent/JP6585600B2/ja active Active
- 2014-12-23 US US15/107,884 patent/US11208497B2/en active Active
- 2014-12-23 KR KR1020167019769A patent/KR20160122127A/ko not_active Withdrawn
- 2014-12-23 MX MX2016008355A patent/MX2016008355A/es unknown
- 2014-12-23 SG SG11201605093VA patent/SG11201605093VA/en unknown
- 2014-12-23 WO PCT/CA2014/051263 patent/WO2015095972A1/en not_active Ceased
- 2014-12-23 RU RU2016129724A patent/RU2016129724A/ru unknown
- 2014-12-23 AU AU2014373593A patent/AU2014373593B2/en active Active
-
2016
- 2016-06-21 IL IL246371A patent/IL246371A0/en unknown